Xiaoyi Zhang

Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models

Kelly M Credille, Donald Paul, Yu-Hua Hui, 2014, Molecular Cancer Therapeutics.

Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies

M. Uhlik, Sheng-Bin Peng, Xiaoyi Zhang, 2016, PloS one.

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.

P. Hipskind, D. Clawson, D. Manglicmot, 2015, Journal of medicinal chemistry.

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.

Xiwen Ma, Shih-Hsun Chen, G. Plowman, 2015, Cancer cell.

Inhibition of RAF Isoforms and Active Dimers by LY 3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers Graphical

Xiwen Ma, Shih-Hsun Chen, G. Plowman, 2015 .

Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma*

S. Estrem, Jiangang Liu, Sheng-Bin Peng, 2012, The Journal of Biological Chemistry.

Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models

M. Uhlik, Sheng-Bin Peng, Xiaoyi Zhang, 2014, Molecular Cancer Therapeutics.